Statins Tied To Lower Glaucoma Risk, 60% Fewer Laser Treatments

A Familiar Cholesterol Drug May Also Offer the Eyes Some Protection

A cholesterol drug millions of adults already take is tied to a lower chance of receiving laser treatment for glaucoma. In a large new analysis of medical records, glaucoma patients who took statins were up to 60 percent less likely to undergo the procedure, and adults who took statins were about 10 to 15 percent less likely to be diagnosed with open-angle glaucoma in the first place.

Glaucoma is the world’s leading cause of irreversible blindness. It permanently damages the optic nerve, the cable that carries images from the eye to the brain, and more than 111 million people are expected to have it by 2040. Doctors can change only one proven risk factor, pressure inside the eye, and treatment aims to lower it. Yet many patients keep getting worse anyway, which has researchers hunting for other ways to protect the nerve.

Statins are generally well tolerated, the authors note, and have been drawing growing scientific attention for possible nerve-protecting effects. The new analysis, published in the British Journal of Ophthalmology by researchers at the University of South Florida, the University of Southern California and the University of California San Diego, checked whether that protection shows up in real-world records.

Records of Over 420,000 Adults Link Statins to Lower Glaucoma Risk

Instead of assigning anyone to take a pill, the team looked back at records in a database that pools anonymized data from 115 healthcare organizations and about 165 million people. Of the more than 13 million adults 40 and older with a statin on record, about 223,000 had seen an eye doctor in the prior year and had no earlier glaucoma diagnosis. Researchers paired those statin users with non-users who were alike in age, sex, race, smoking history, other health conditions and more, leaving 210,701 people in each group. That setup is meant to keep other differences from skewing the results.

Before the pairing, statin users averaged about 63 years old, versus about 59 for non-users. Statin users were 56 percent women, 67 percent White, 17 percent Black and 11 percent Hispanic or Latino.

A second analysis zeroed in on people who already had glaucoma, matching 29,598 statin users with 29,598 non-users and tracking who went on to receive eye drops, surgery or laser treatment. Records spanned 2006 to 2026, with follow-up of up to ten years.

Glaucoma Patients on Statins Had Fewer Laser Treatments and Surgeries

Among patients who already had glaucoma, the gap was widest for laser treatment. After five years, statin users were 60 percent less likely to have it, which works out to roughly 2 of every 100 statin users versus nearly 6 of every 100 non-users. Minimally invasive surgery, a gentler operation, was 55 percent less likely, and traditional surgery was 36 percent less likely. Prescriptions for pressure-lowering eye drops, a far more common treatment, were 11 percent less likely.

New diagnoses told a quieter story. At five years, about 23 of every 1,000 statin users had been diagnosed with open-angle glaucoma, compared with 26 of every 1,000 non-users. In plain numbers, that works out to about three fewer diagnoses per 1,000 people: real but modest.

By ten years, the benefit had narrowed but held up. Diagnoses were about 10 percent lower, and laser treatment was about half as likely.

Not every statin behaved the same way. Atorvastatin and rosuvastatin users matched the overall pattern, while simvastatin and pravastatin users showed no clear difference in new diagnoses, though they underwent laser treatment and minimally invasive surgery less often. Those groups were much smaller, which the authors said may explain the mixed results.

Records Alone Cannot Prove Statins Prevent Glaucoma

None of this shows that statins caused the differences. The authors write that “causality cannot be inferred,” and the records have blind spots. They hold no eye pressure readings or vision tests, and they do not say why each procedure was done. Fewer laser treatments therefore do not automatically mean slower disease, since a procedure might happen for other reasons, such as trouble using eye drops.

Earlier research points both ways. Several studies found protective links like this one, while others tied long-term statin use to higher eye pressure and greater glaucoma risk, which the authors say may fit with the slightly weaker protection at ten years.

How statins might protect the eye is still unsettled. The paper points to calmer immune activity, better blood flow to the optic nerve and, in one pig-eye study, improved fluid drainage that could lower pressure. This analysis tested none of those ideas.

Statins May Guard Against Glaucoma, but Trials Are Needed

Settling the question will take randomized trials, which assign people to take a drug or not and can show cause directly. The authors call for exactly that.

A drug millions already take could turn out to protect the eyes, too, and the lower laser rates make that worth testing. Until a trial confirms it, though, nobody should start a statin to guard against glaucoma, and lowering eye pressure remains the approach with proven results.

---

Disclaimer: This article reports on a published research paper and is for informational purposes only. It is not medical advice. Anyone with questions about statins, glaucoma or eye health should talk with a qualified healthcare professional, and nobody should start or stop a medication based on this report.

---